

In the Claims:

Please cancel claims 43, 49, 50, 54 and 55.

Please amend the claims to read as follows:

42. (Amended) An isolated recombinant human adenine nucleotide translocator polypeptide that localizes to a mitochondrial membrane, that is capable of binding an ANT ligand and that is produced by a method comprising culturing a host cell comprising a recombinant expression construct comprising at least one regulated promoter operably linked to a nucleic acid encoding the adenine nucleotide translocator polypeptide.

46. (Amended) The isolated polypeptide of claim 42 wherein the human adenine nucleotide translocator polypeptide is recombinant ANT3 or a variant or fragment thereof.

47. (Amended) An isolated recombinant human adenine nucleotide translocator fusion protein comprising an adenine translocator polypeptide fused to at least one additional polypeptide sequence, wherein the fusion protein localizes to a mitochondrial membrane and is capable of binding an ANT ligand.

51. (Amended) An isolated human adenine nucleotide translocator fusion protein comprising an adenine translocator polypeptide fused to at least one additional polypeptide sequence cleavable by a protease, said adenine nucleotide translocator polypeptide being capable of localizing to a mitochondrial membrane and capable of binding an ANT ligand and separable from the fusion protein by cleavage with the protease.

52. (Amended) An isolated adenine nucleotide translocator fusion protein comprising a first polypeptide that is an animal adenine translocator polypeptide that is capable of localizing to a mitochondrial membrane and capable of binding an ANT ligand and that is fused to at least one additional polypeptide sequence.